Novosanis & nRichDX logos

Liquid Biopsy from Urine - Current Perspectives Webinar

Live Webinar: Thursday, 22 September 2022 at 4 pm CET / 10 am EST
 
Molecular Profiling of Urine for Prostate Cancer Diagnosis:
Opportunities and Challenges
 
Keynote speaker: Dr. Simpa Salami, Assistant Professor of Urology at the University of Michigan and Co-Director, Liquid Biopsy Core, Rogel Cancer Center.
 

Please complete the Webinar Registration Form below and click the "Register Now" button.
Webinar registrants will also receive a link to the recorded webinar.
 

Presenters

Simpa Salami headshot for LP

Simpa Salami, PhD, MPH

Assistant Professor of Urology at the University of Michigan and Co-Director, Liquid Biopsy Core, Rogel Cancer Center

Dr. Salami is a translational surgeon-scientist whose research interests are in early detection and staging of prostate and kidney cancer. He seeks to leverage novel imaging, machine learning, and next generation sequencing and molecular profiling approaches to characterize cancer heterogeneity and tumor multifocality.


Nafiseh Jafari headshot for LP

Nafiseh Jafari, PhD

Director of R&D at nRichDX

Dr. Jafari will provide a brief overview of the Revolution Sample Prep System® for extraction of circulating nucleic acids (cfNA, including cfDNA, ctDNA, and cfRNA) from urine and plasma samples.


Amit Arora headshot for LP

Amit Arora, PhD

Sr. Scientist, R&D at DNA Genotek

Dr. Arora will provide a brief overview on the Colli-Pee® device and UAS™ preservative for the standardized volumetric collection of the urine samples and urinary analytes preservation, respectively

*Novosanis NV and DNA Genotek Inc., are subsidiaries of OraSure Technologies, Inc.